A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM

Neurology

Volumn 56, Issue 3, 2001, Pages 323-327

  Dalakas, Marinos C ^a   Koffman, B ^a   Fujii, M ^a   Spector, S ^a   Sivakumar, K ^a   Cupler, E ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD2 ANTIGEN; IMMUNOGLOBULIN G; PLACEBO; PREDNISONE;

AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG MEGADOSE; FOLLOW UP; HUMAN; INCLUSION BODY MYOSITIS; INFLAMMATION; MUSCLE BIOPSY; MUSCLE NECROSIS; MUSCLE STRENGTH; PATIENT SATISFACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE; TREATMENT OUTCOME;

EID: 0035852876     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.56.3.323     Document Type: Article

References (27)

1. Inclusion body myositis and myopathies
2. Inclusion body myositis: New concepts
3. The polymyositis and dermatomyocitis syndrome
4. Polymyositis, dermatomyositis, and inclusion body myositis
5. Pathology of the inflammatory myopathies
6. Molecular immunology and genetics of inflammatory muscle diseases
7. T-cell heterogeneity in muscle lesions of inclusion body myositis
8. Expression of cell adhesion molecules in inflammatory myopathies and Duchenne dystrophy
9. Expression of the costimulatory molecule BB-1, the ligands CTLA-4 and CD28, and their mRNA in inflammatory myopathies
10. Autoimmune diseases and autoantibodies association with sporadic inclusion body myositis
11. Intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: Present status and practical therapeutic guidelines
12. Treatment of inclusion-body myositis with high-dose intravenous immunoglobulin
13. Inclusion body myositis: Treatment with intravenous immunoglobulin
14. Treatment of inclusion body myositis with IVIg: A double-blind, placebo-controlled study
15. High-dose immunoglobulin therapy in sporadic inclusion body myositis: A double-blind, placebo-controlled study
16. A controlled trial of high-dose intravenous immunoglobulin infusions as treatment for dermatomyositis
17. Treatment of Guillain-Barre' syndrome with high-dose immune globulins combined with methylprednisolone: A pilot study
18. Clinical investigation in Duchenne dystrophy II: Determination of the power of the therapeutic trials based on natural history
19. Use of composite scores (megascores) to measure deficit in amyotrophic lateral sclerosis
20. Disease progression in sporadic inclusion body myositis (s-IBM): Observations in 78 patients
21. Multiple mitochondrial DNA deletions in sporadic inclusion body myositis: A study of 56 patients
22. Loss and renewal of thick filaments in glucocorticoid-treated rat soleus after denervation and reinnervation
23. Intravenous immune globulin therapy for neurological diseases
24. Inclusion body myositis: Explanation for poor response to immunosuppressive therapy
25. Downregulation of TGF-β1 mRNA and protein in the muscles of patients with inflammatory myopathies after treatment with high-dose intravenous immunoglobulin (IVIg)
26. The therapeutic dilemma of inclusion body myositis
27. A natural history study of inclusion-body myositis